The deal priced at low end of $3.20-$3.40 range. Leerink and Guggenheim are acting as joint book running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics TBA Spot Secondary; price range $3.20-$3.40
- Larimar Therapeutics announces common stock offering, no amount given
- Promising Potential of Larimar Therapeutics’ Nomlabofusp in Friedreich’s Ataxia: A Buy Rating Justified
- Positive Outlook for Larimar Therapeutics: Promising Data on Nomlabofusp and Anticipated Catalysts Drive Buy Rating
- Larimar Therapeutics’ nomlabofusp shows therapeutic potential in FA